Get the Stockscreener App
327.77
2.74%
8.73
After Hours:
327.77
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Waters Corp stock is traded at $327.77, with a volume of 439.18K.
It is up +2.74% in the last 24 hours and up +10.36% over the past month.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
See More
Previous Close:
$319.04
Open:
$321.04
24h Volume:
439.18K
Relative Volume:
0.40
Market Cap:
$32.18B
Revenue:
$3.17B
Net Income/Loss:
$642.63M
P/E Ratio:
30.45
EPS:
10.765
Net Cash Flow:
$516.49M
1W Performance:
+2.43%
1M Performance:
+10.36%
6M Performance:
-2.04%
1Y Performance:
+2.11%
1-Day Range:
$318.96
$329.56
1-Week Range:
$316.24
$333.68
52-Week Range:
$275.05
$414.15
Waters Corp Stock (WAT) Company Profile
Name
Waters Corp
Sector
Industry
Phone
(508) 478-2000
Address
34 MAPLE ST, MILFORD, MA
Compare WAT vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WAT
Waters Corp
|
327.77 | 32.18B | 3.17B | 642.63M | 516.49M | 10.77 |
TMO
Thermo Fisher Scientific Inc
|
526.60 | 195.70B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.75 | 137.82B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
589.25 | 46.80B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
121.87 | 34.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Waters Corp Stock (WAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-10-26 | Resumed | Barclays | Overweight |
| Feb-10-26 | Resumed | Citigroup | Buy |
| Feb-10-26 | Resumed | Evercore ISI | In-line |
| Jan-06-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-10-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-02-25 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-08-25 | Initiated | Rothschild & Co Redburn | Buy |
| Mar-31-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-26-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Feb-10-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-08-24 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Nov-13-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-31-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| May-18-22 | Initiated | Barclays | Overweight |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-25-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-07-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-17-20 | Upgrade | Cleveland Research | Underperform → Buy |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-28-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-16-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-08-20 | Downgrade | Needham | Hold → Underperform |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Sell |
| Nov-15-19 | Initiated | Stifel | Hold |
| Oct-09-19 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-16-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-12-19 | Downgrade | Cleveland Research | Neutral → Underperform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| Jan-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jan-03-19 | Initiated | Needham | Hold |
| Dec-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-30-18 | Downgrade | Goldman | Neutral → Sell |
| Oct-11-18 | Upgrade | Cleveland Research | Sell → Neutral |
View All
Waters Corp Stock (WAT) Latest News
Waters Corp stock (US94106L1098): Why Google Discover changes matter more now - AD HOC NEWS
Waters Corp. stock outperforms competitors on strong trading day - MarketWatch
Waters prices $3.5B senior notes offering - MSN
Waters Corp. stock outperforms competitors despite losses on the day - MarketWatch
Senate overturns Boundary Waters protections, a boon for Chilean mining company - CNBC
New Southern Waters company the biggest in South Island - The Central App
Waters Corporation $WAT Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Short Interest in Waters Corporation (NYSE:WAT) Increases By 29.0% - MarketBeat
Waters Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
WAT SEC FilingsWaters 10-K, 10-Q, 8-K Forms - Stock Titan
Waters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis - Finviz
Waters Corporation's Q1 2026 Earnings: What to Expect - Yahoo Finance
Waters Corp stock (US94106L1098): Why its leadership in analytical instruments matters more now for - AD HOC NEWS
Boston Trust Walden Balanced Fund's Waters Corp(WAT) Holding History - GuruFocus
Waters Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules - marketscreener.com
Cardinal Capital Management's Waters Corp(WAT) Holding History - GuruFocus
Waters Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Big Picture: Will Waters Corporation outperform small cap indexes2026 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Street Calls of the Week By Investing.com - Investing.com India
IAWAI growth assumptions questioned as waters company prepares strategy - Waikato Times
WAT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Cambiar Investors LLC Sells 4,954 Shares of Waters Corporation $WAT - MarketBeat
Massachusetts Financial Services Co. MA Sells 64,978 Shares of Waters Corporation $WAT - MarketBeat
Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results - ADVFN
Waters Corporation (NYSE: WAT) Reports First Quarter 2021 Financial Results - ADVFN
Waters Corp Achieves Highest Daily Trading Volume of $270 Million, Rising 0.74% as Earnings Outlook Adjusts - Bitget
Waters Corporation (WAT) stock price, news, quote and history - Yahoo Finance Australia
WAT Earnings History & Surprises | EPS & Revenue Results | WATERS CORP (NYSE:WAT) - ChartMill
Waters (NYSE: WAT) highlights BD acquisition, 7% 2025 growth and performance-linked executive pay - Stock Titan
HARTFORD HEALTHCARE HLS FUND's Waters Corp(WAT) Holding History - GuruFocus
Rep. Gilbert Ray Cisneros, Jr. Buys Waters Corporation (NYSE:WAT) Stock - MarketBeat
Waters (WAT) Gains FDA Clearance for At-Home Cervical Cancer Scr - GuruFocus
Waters Corp Stock Surges on FDA Clearance: What Investors Need to Know Now - AD HOC NEWS
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening KitWaters (NYSE:WAT) - Benzinga
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay - Finviz
US FDA approves Waters' at‑home cervical cancer screening kit - Reuters
Waters (WAT) Gains FDA Approval for At-Home Cervical Cancer Scre - GuruFocus
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay – Company AnnouncementFT.com - Financial Times
Waters Corp stock: What investors need to know in today's market - AD HOC NEWS
[Form 4] WATERS CORP /DE/ Insider Trading Activity - Stock Titan
Waters Corporation (NYSE:WAT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Evercore ISI upgrades Waters stock rating on achievable targets By Investing.com - Investing.com Australia
Evercore ISI upgrades Waters stock rating on achievable targets - Investing.com
Waters Corp : Evercore ISI Raises to Outperfo - Moomoo
Manufacturing Excellence Awards 2026: Waters Corp. - Worcester Business Journal
WAT Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Waters Corporation (WAT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Waters Corp (WAT) director gets deferred stock units grant - Stock Titan
Director Heather Knight granted deferred Waters (NYSE: WAT) stock units - Stock Titan
Waters Corp (MIL:1WAT) Bonds - GuruFocus
Waters Corp Stock (WAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):